Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2013) 1 PP110 | DOI: 10.1530/boneabs.1.PP110

1Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus, Denmark; 2Department of Pharmacology, Aarhus University Hospital, Aarhus, Denmark.


Despite the substantial preclinical evidence for a positive effect of the polyphenolic compound resveratrol, human data are very scarce, and currently no clinical data addressing the potential impact on bone metabolism have been published. In the present study we addressed this issue by testing a panel of bone specific biomarkers in order to identify potential bone metabolic effects of resveratrol in human subjects. In a randomized, placebo-controlled, double-blinded and parallel-group design, 24 obese (BMI (kg/m2): 34.2±0.7) non-diabetic men were randomly assigned to 500 mg resveratrol or placebo treatment three times daily for four weeks. Biomarkers of bone metabolism, inflammatory parameters, circulating hormones and DXA scans were measured before and after the intervention period. Plasma levels of bone-specific alkaline phosphatase increased significantly in the resveratrol group as compared to placebo (delta changes (U/l); placebo: −1.7±0.7 vs resveratrol: 4.9±0.6; P<0.001). This was paralleled by a tendency of total alkaline phosphatase to rise within the resveratrol group (P=0.061), whereas no changes were detected in other biomarkers of bone metabolism, including PINP, osteocalcin, CTx, or PTH. We suggest that resveratrol represent a primary anabolic modality in preserving bone integrity by possible interference with the mineralization process. The clinical implications remain to be evaluated.

Volume 1

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.